phase readout
saveTrial primary completion: Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan
November 6, 2026updated 20d ago
community read0 votes
Sponsor: Sanofi. Status: Active, not recruiting. Conditions: Fabry Disease. NCT06052800.
view source ↗Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that